• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Cancer biomarker Companies

    ID: MRFR/HC/3935-CR
    200 Pages
    Rahul Gotadki
    July 2025

    Cancer biomarkers are measurable indicators associated with the presence or progression of cancer. Detection and analysis of these biomarkers play a crucial role in cancer diagnosis, prognosis, and treatment monitoring. Numerous companies are actively involved in the research, development, and commercialization of cancer biomarker technologies.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Cancer biomarker Market Research Report - Global Forecast till 2035 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Cancer biomarker Market

    Cancer Biomarker Ket CompaniesLatest Cancer Biomarker Companies Update



    • Nov 2023: A new agreement has been signed by XtalPi, a leading worldwide technology firm that combines robotics and artificial intelligence (AI) to drive the discovery of novel materials and breakthrough medical treatments, and CK Life Sciences, a part of the CK Hutchison Group. Expanding on their current collaboration, the two businesses will work together to explore and create miRNA-based postoperative molecular diagnostic systems for prognostic risk prediction. To do this, they will merge AI algorithms with privatized clinical and biomarker data from cancer patients and healthy individuals stored in CK Life Sciences' data repository. This collaborative engagement should result in creating more sophisticated and intelligent solutions for analyzing and modeling comprehensive multidimensional biological data, biomarker exploration, and postoperative recurrence risk with the aid of AI and machine learning models.



    • The health tech startup IMVARIA Inc., leading the way in AI-driven digital biomarker solutions, announced a knowledge-sharing partnership with Mayo Clinic to jointly develop AI intended to dramatically enhance the analysis and comprehension of cancer, starting with lung cancer. With a distinctive platform developed by co-founders that include engineers, doctors, and former Google employees, IMVARIA's team of professionals is fixated on creating and improving digital biomarkers to improve patient outcomes. As a component of the Validate pillar of the Mayo Clinic Platform, the partnership combines the engineering know-how of IMVARIA in digital biomarkers with the knowledge and data assets of the Mayo Clinic. The extensive and dependable training of AI "brains" to find and validate clinically significant software-only biomarkers for cancer will be made possible by large-scale datasets.


    List of Cancer Biomarker Key companies in the market


    • Becton Dickinson (U.S.)




    • Merck & Co.Inc. (U.S.)




    • Novartis AG (Switzerland)




    • PerkinElmer Inc. (U.S.)




    • F. Hoffmann-La Roche AG (Switzerland)




    • Bio-Rad Laboratories (U.S.)




    • Illumina Inc. (U.S.)




    • Thermo Fisher Scientific Inc. (U.S.)




    • Abbott Laboratories (U.S.)




    • GlaxoSmithKline plc. (U.S.)



    •